資源描述：
《阿侖膦酸鈉治療絕經(jīng)后骨質(zhì)疏松癥的臨床觀察.doc》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、阿侖麟酸鈉治療絕經(jīng)后骨質(zhì)疏松癥的臨床觀察中國(guó)骨質(zhì)疏松雜志2000年第2期第23卷論著作者：肖建徳閻徳文吳清平李卓成吳建龍孫月玲單位：肖建徳(518029深圳市紅十字會(huì)醫(yī)院)；閻徳文(518029深圳市紅十字會(huì)醫(yī)院)；吳清平(518029深圳市紅十字會(huì)醫(yī)院)；李卓成(518029深圳市紅十字會(huì)醫(yī)院)；吳建龍<518029深圳市紅十字會(huì)醫(yī)院)；孫月玲(518029深圳市紅十字會(huì)醫(yī)院)關(guān)鍵詞：臨床研究；阿侖麟酸鈉；絕經(jīng)后骨質(zhì)疏松；骨密度摘要目的評(píng)價(jià)阿侖麟酸鈉治療骨質(zhì)疏松癥的近期臨床療效和安全性。方法絕經(jīng)后骨質(zhì)疏松患
2、者34例(診斷條件：按WHO標(biāo)準(zhǔn)診斷骨質(zhì)疏松，自然絕經(jīng)后，臨床上排除其他繼發(fā)疾病，肝腎功能、血鈣、血磷、血ALP止常)，連續(xù)服用阿侖麟酸鈉(lOmg/d,-早餐前頓服)和碳酸鈣(凱思立D500mg/d或鈣爾奇D600mg/d晚餐前頓服),6個(gè)月后復(fù)測(cè)患者骨密度，包括腰椎(L2-4)止、側(cè)位(APL2-4,LatL2-4)和左股骨近端(Total)及股骨頸(Neck)；在服約期間每月隨診一次，觀察患者臨床癥狀、肝腎功能、血鈣、血磷、血ALP以及血常規(guī)和晨尿梵脯氨酸(Hop/Cr)等生化指標(biāo)的變化。結(jié)果治療后骨密
3、度明顯上fF(APL2-40.768±0.097vs0.792±0.094,P<0.05,LatL2-40.528±0.113vs0.551±0.101,P<0.05,Neck0.585±0.094vs0.611±0.075,P<0.05,Total0.684±0.107vs0.701±0.093,P<0.05),各部位骨密度平均增長(zhǎng)率分別為3.28%、4.41%、4.77%、2.56%；在服藥1?3月內(nèi)骨痛緩解;血鈣水平升高(P<0.01),?血ALP水平和晨尿Hop/Cr值下降(PV0.01)；肝腎功能及
4、血常規(guī)無(wú)異滋改變；主觀消化道不適發(fā)生率為22.86%,多可自行緩解。結(jié)論阿侖瞬酸鈉近期治療絕經(jīng)后骨質(zhì)疏松癥是安全、有效的。ClinicaltrialofalendronateintreatmentofpostmenopausalosteoporosisXiaoJiande,YanDewen,WuQingping^etal.DepartmentofOrthopedics,ShenzhenRedCrossHospital,Shenzhen518029,ChinaAbstractObjectiveTotestthe
5、efficacyandsafetyofalendronatesodium(ALN)intreatmentofpostmenopausalosteoporosis.MethodsParametersofboneremodelling,lumbarspine(APL2-4,LatL2-4)andfemoral(Neck.Total)bonemineraldensity(BMD)wereassessedin34postmenopausalwomenwithosteoporosis(BMDt-score<-2.5).
6、TheyreceivedALN(lOmg/d)andcalciumcarbonate(500-600mg/d)for6months.TheefficacywasdeterminedbythechangeofBMDparametersofboneremodelling(serumalkalinephosphatase,ALPandfastingurinaryhydroxyprolineexcretion,HOP/Cr)^indtheimprovementofclinicalsymptomsbeforeandaf
7、terthetrial.ResultsBMDatallskeletalsitessignificantlyincreasedaftertreatmentfor6months:APL2-40.768±0.097vs0.792±0.094,P<0.05,LatL2-40.528±0.113vs0.551±0.101,P<0.05,Neck0.585±0.094vs0.611±0.075,P<0.05,Total0.684±0」07vs0.701±0.093,P<0.05);theratesofchangewere
8、3.28%inAPL2?4,4.41%inLatL2-4,4.77%inNeck,and2.56%inTotal.SerumALPandurinaryHop/Crsignificantlydecreasedaftertreatment.Serumcalciumincreasedandserumphosphatedecreasedmarkedly.butbothwithinthenormalrange
